Lung cancer patients have brighter prospects of survival after surgery. A clinical trial has shown that combination chemotherapy given after complete surgical removal of early-stage lung cancer significantly prolongs patients' survival.
Lung cancer patients have brighter prospects of survival after surgery. A clinical trial has shown that combination chemotherapy given after complete surgical removal of early-stage lung cancer significantly prolongs patients' survival.Researchers from the National Cancer Institute of Canada conducted a study involving 482 patients with non-small-cell lung cancer, a common type of the disease. After surgery, those treated for 16 weeks with a combination of two chemotherapy drugs - vinorelbine and cisplatin, survived an average of 94 months. But those who were given no chemotherapy after surgery, survived for 73 months. Sixty-nine percent of the vinorelbine/cisplatin group survived at least 5 years compared with 54 percent of the surgery-only group. The time before recurrence of the cancer was also significantly longer in the vinorelbine/cisplatin group.
This study should solidify opinion in favour of changing the standard of care for these patients. A 15 percent overall survival benefit 5 years after surgery and prolonged disease-free survival in this population are major advances.
American Society of Clinical Oncology Meeting,
June 2004
June 2004
COMMENT
DoctorNDTV is the one stop site for all your health needs providing the most credible health information, health news and tips with expert advice on healthy living, diet plans, informative videos etc. You can get the most relevant and accurate info you need about health problems like diabetes, cancer, pregnancy, HIV and AIDS, weight loss and many other lifestyle diseases. We have a panel of over 350 experts who help us develop content by giving their valuable inputs and bringing to us the latest in the world of healthcare.
